Symbols

BLRX

BioLineRx·NASDAQ

--(--)

BLRX fundamentals

BLRX Q4 2025 Earnings

BioLineRx (BLRX) released its earnings on Mar 23, 2026: revenue was 514.00K (YoY -95.63%), met estimates; EPS was -0.385 (YoY +75.94%), met estimates.

Revenue / YoY

514.00K

-95.63%

EPS / YoY

-0.385

+75.94%

Report date

Mar 23, 2026

BLRX Earnings Call Summary for Q4,2025

GLIX1 Milestone: GBM Phase I/IIa trial to enroll first patients in March 2026, targeting $3.7B market with 90% cancer coverage.
Financial Stability: $21M cash runway to H1 2027; resolved $7.2M legal claim, freeing resources for R&D.
Trial Progress: CheMo4METPANC trial enrollment accelerating; GLIX1 patent extends to 2040 with broad cancer applicability.
Key Risks: GBM trial focused on safety; no interim efficacy data; APHEXDA sales dependent on Ayrmid's private strategy.

Earnings

EPS

Revenue

Revenue & Expenses

BLRX has released its 2025 Q4 earnings report, with revenue of 194.00K, reflecting a YoY change of -98.35%, and net profit of -2.24M, showing a YoY change of 29.84%. The Sankey diagram below clearly presents BLRX's revenue sources and cost distribution.

Key Indicators

BioLineRx (BLRX) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

BioLineRx (BLRX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

BioLineRx (BLRX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

BioLineRx (BLRX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown